LOXO Overview
Upcoming Projects (LOXO)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (LOXO)
-
Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4
Tickers: LOXO, EXEL, RXDX, NVS
Execute By: Dec 12, 2017
Upcoming & Overdue Catalysts (LOXO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (LOXO)
-
Breakthrough Therapy Designation from U.S. FDA for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
Ticker: LOXO
Occurred on: Oct 15, 2018 -
Loxo Oncology(LOXO) Interim Phase 1 LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at ASCO
Ticker: LOXO
Occurred on: Jun 02, 2018 -
Top-Line Results from Independent Review Committee Assessment of Loxo Oncology's Larotrectinib Dataset Released
Ticker: LOXO
Occurred on: Oct 18, 2017 -
Loxo Oncology Receives Breakthrough Therapy Designation from FDAfor LOXO-101
Ticker: LOXO
Occurred on: Jul 13, 2016
Strategic Initiatives (LOXO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
